ABAdinda Baten

Adinda Baten

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adinda Baten has a total of 140 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tamoxifen use increases endometrial cancer risk in premenopausal breast cancer patients

    by Zoe Molinari, Nancy Van Damme, Julie Verbeeck, Annouschka Laenen, Sileny N. Han, Maxime Van Houdt, Dirk Timmerman, Ann Smeets, Ines Nevelsteen, Yannick Van Herck, et al.

    Tamoxifen increases the risk of endometrial cancer (ECa) when treating breast cancer (BC)in postmenopausal women, but the impact in premenopausal women is not well established. A retrospective study in South-Korea suggested that premenopausal BC patients were 3.77 times more likely to develop ECa when treated with tamoxifen. We aimed to validate these results in a large-scale nationwide study in Belgium.We conducted a retrospective cohort study in women, aged 18–53, diagnosed with non-metastatic BC in Belgium between 2008 and 2020. Patients treated with tamoxifen were compared to those not treated with tamoxifen by baseline characteristics and diagnosis of ECa. The primary endpoint was time to ECa diagnosis. A Cox proportional hazards model assessed the primary endpoint, with treatment group as the main variable and patient/tumor characteristics as covariates.We included 23 289 patients (60%; median age 47 years) in the tamoxifen group and 15 568 patients (40%; median age 47 years) in the non-tamoxifen group. Tamoxifen users were more likely to have low-grade and lobular tumors, and less likely to receive (neo-)adjuvant or targeted (chemo)therapy. 96 ECa events occurred in the tamoxifen group (0.41%) and 27 in the non-tamoxifen group (0.17%). This translated to 0.51% and 0.22% of survivors, respectively which was a statistically significant difference (HR 2.05, CI: 1.34-3.15). After adjusting for potential confounders—diabetes, cardiovascular profile, tumor grade, pT, pN, chemotherapy, and targeted therapy—the risk remained significantly elevated in the tamoxifen group (adjusted HR 1.93, CI: 1.14-3.28; p = 0.0141).

  • Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy

    by Daan Dierickx, Joosje H. Heimovaara, Mar Bellido, Kristel Van Calsteren, Elyce Cardonick, Alvaro Cabrera Garcia, Adinda Baten, Andrew M. Evens, Andres Ferber, Monica Fumagalli, et al.

    The diagnosis and treatment of hematologic malignancies has undergone significant advancements over the past few decades, resulting in enhanced outcomes. For hematologic malignancies diagnosed during pregnancy, this poses new questions. As possibilities continue to expand and the rising global incidence results in an increasing number of diagnoses within the pregnant population, there is a pressing need to gain a deeper understanding of the potential options for pregnant women and the impact on the newborn. As knowledge of the effects of cancer treatment increases, more women are receiving adequate cancer diagnosis and treatment during pregnancy. This paper presents an expert opinion on the use of diagnostic modalities and treatment options, including chemotherapy, radiation therapy, and immunotherapy, for acute leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, myeloproliferative neoplasms, aplastic anemia, and multiple myeloma during pregnancy.

  • Open Access

    Twenty‐year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I–III breast cancer

    by Orit Kaidar‐Person, Caroline G. Weltens, Catherine Fortpied, Luc J. E. E. Scheijmans, Carine Y. Kirkove, Volker Budach, Karine Peignaux‐Casasnovas, Mariacarla Valli, Max Peters, Femke van der Leij, et al.

    European Organization for Research and Treatment of Cancer trial EORTC 22922/10925 evaluated internal mammary and medial supraclavicular (IM‐MS) lymph node irradiation (IM‐MS‐RT) in patients with stage I–III breast cancer. Eligible patients had involved axillary nodes and/or centrally/medially located tumors regardless of nodal involvement. The primary end point was overall survival, secondary end points were disease‐free survival, distant metastases‐free survival, breast cancer mortality, and any breast recurrence. Between 1996 and 2004, 4004 patients were randomized. The median patient age was 54 years. At a median follow‐up of 22.2 years, 1550 (38.7%) patients died, of whom 796 (51.4%) died from breast cancer. At 20 years, the overall survival rate was 61.8% in the control group versus 61.0% in the IM‐MS‐RT group (hazard ratio [HR], 1.00; p = .967); the disease‐free survival rate was 49.0% versus 48.2%, respectively (HR, 0.97; p = .515); and the distant metastases‐free survival rate was 59.8% versus 58.9%, respectively (HR, 0.97; p = .578). The breast cancer mortality rate was 22.4% in the control group and 18.6% in the IM‐MS‐RT group (HR, 0.82; p = .006), whereas the rate of deaths not from breast cancer or from unknown causes was 15.8% versus 20.4%, respectively (HR, 1.26; p = .002). Lung fibrosis, cardiac fibrosis, and cardiac diseases were more frequent after IM‐MS‐RT versus no IM‐MS‐RT (6.3% vs. 3.2%, 2.7% vs. 1.7%. and 15.2% vs. 11.7%, respectively); and the rates of severe cardiac and lung morbidities (scores of 3 or 4) were 1.9% versus 1.7% and 0.3% versus 0.0%, respectively. Breast cancer mortality at 20 years was statistically significantly lower after IM‐MS‐RT, but deaths not from breast cancer increased after 15 years, resulting in no long‐term benefit of IM‐MS‐RT on overall survival. Therefore, the authors strongly call for very long‐term follow‐up of treatments for prognostically favorable cancers such as breast cancer.


  • Open Access

    Continuous positive airway pressure in breast cancer radiotherapy: protocol of a prospective clinical trial

    by Aline Van der Vorst, Jelle Verhoeven, Adinda Baten, Hilde Janssen, Lander Van Bavel, Laurence Delombaerde, Truus Reynders, Marie Cooreman, Annouschka Laenen, Maarten Lambrecht, et al.

    BackgroundRadiotherapy (RT) improves survival and local control after breast-conserving surgery (BCS) for breast cancer (BC) but can also cause toxicity. Preliminary studies suggest that continuous positive airway pressure (CPAP) reduces organ-at-risk (OAR) doses in left-sided BC RT. This prospective trial evaluates whether CPAP reduces OAR doses in a larger patient cohort, including both left and right-sided cases, and identifies which patients benefit most. Furthermore, this study investigates the feasibility of CPAP in BC RT, by evaluating patient comfort, radiation time, accuracy and reproducibility.MethodsBC patients requiring BCS and RT are prospectively enrolled —left-sided cases with or without regional nodal irradiation (RNI), or right-sided cases requiring RNI. Each patient undergoes an additional CT simulation with CPAP—free breathing (FB) for right-sided cases and deep inspiration breath hold (DIBH) for left-sided cases. Left-sided patients unable to perform DIBH or ≥70 years old are evaluated in FB. Two RT plans (with and without CPAP) are compared. If CPAP reduces mean heart or contralateral breast dose by ≥0.5Gy, or mean lung dose by ≥1Gy, treatment is delivered with CPAP. Patient comfort is assessed through surveys. Sample size calculations indicated that 53 patients are required to detect a ≥0.5Gy reduction in mean heart dose.DiscussionThis is the first large, prospective study to evaluate CPAP in both left- and right-sided BC patients, aiming to demonstrate OAR dose reductions and assess feasibility. The final aim is to provide patient-selection models and guidelines for clinical implementation.Trial registration: The study is registered on Clinicaltrials.gov (NCT07373782).

  • Open Access

    Radiation therapy management in BRCA1/2 carriers diagnosed with early breast cancer: An international cohort study

    by Carlotta Becherini, Eva Blondeaux, Virginia Delucchi, Luca Visani, Hee Jeong Kim, Florence Coussy, Rinat Bernstein-Molho, Antonio Di Meglio, Florentine S. Hilbers, Katarzyna Pogoda, et al.


  • Open Access

    Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial

    by A De Caluwé, S. Bellal, K. Cao, K. Peignaux, V. Remouchamps, A. Baten, E. Longton, I. Bessieres, J. Vu-Bezin, Y. Kirova, et al.


  • Radiation-induced heart disease in breast cancer patients: a narrative review of epidemiology, risk factors, radiotherapy parameters, and prevention

    by Aline Van der Vorst, Maarten Lambrecht, Lucas Van Aelst, Jelle Verhoeven, Johanna Jacobs, Adinda Baten, Caroline Weltens

    Background Breast cancer is the most prevalent cancer in women worldwide; nevertheless, the prognosis is good, with a 5-year overall survival of 80–90%. Therefore, it becomes crucial to strive for high quality of life after cure by minimizing treatment-related toxicity. One such concern is radiation-induced heart disease, which remains a significant focus of ongoing investigations. Purpose The aim of this review is to summarize current knowledge on radiation-induced heart disease in breast cancer patients by giving an overview of its epidemiology, risk factors, radiation parameters related to its development, solutions in radiation practice, and prevention. The goal is to raise awareness and maximize prevention of radiation-induced heart disease. Methods The PubMed database was screened for articles published between January 2013 and November 2023 related to the keywords , , , and . Moreover, by screening the literature lists of these publications, additional articles were added. Results Ninety-four relevant papers remained for final review. Conclusion Radiation-induced heart disease is a rare complication after breast cancer radiotherapy and represents a clinical spectrum of various cardiovascular conditions. Several heart-sparing techniques have been developed, and more attention has been paid to early diagnosis and prevention of radiation-induced heart disease. However, further research remains important to refine radiotherapy techniques and deepen our understanding for improved prevention and treatment of this condition in the future. This clinical review summarizes the existing evidence and literature on radiation-induced heart disease following modern breast cancer radiotherapy, offering clinical guidance for physicians.


  • Life-threatening paraneoplastic cardiovascular events in ALK-positive anaplastic large cell lymphoma

    by Charlotte Verhaeghe, Björn Meijers, Ann Mertens, Peter R. Sinnaeve, Sander Jentjens, Adinda Baten, F. J. Sherida H. Woei-A-Jin


  • In Regard to Zelefsky et al

    by Kato Rans, Gert De Meerleer, Steven Joniau, Adinda Baten, Patrick Berkovic, Maarten Lambrecht, Charlien Berghen